OPR - Delayed Quote • USD SAVA Jun 2025 30.000 call (SAVA250620C00030000) Follow 8.38 0.00 (0.00%) At close: April 16 at 3:12 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for SAVA250620C00030000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: SAVA Redemption Date Announced for Warrants Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference Cassava Sciences Inc (SAVA) Reports Full-Year 2023 Financial Results Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates Exit Now! 3 Biotech Stocks to Sell in February 2024 No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst retail investors who own 59% of the shares, institutions hold 31% Is There Any Hope for Cassava Sciences Stock? 3 Biotech Stocks to Sell in January Before They Crash and Burn Cassava Sciences Stock Continues Showing Rising Relative Strength
